Actinium Pharmaceuticals, Inc. (API) welcomes you to learn about our therapeutic development pipeline based on our proprietary Alpha Particle Immunotherapy Technology (APIT) platform.API is the leader in the research, development and commercialization of the alpha emitting isotopes bismuth 213 (Bi-213) and actinium 225 (Ac-225) for fighting cancer and other cellular diseases. The Company currently has two clinical trials underway and a number of preclinical initiatives. By utilizing the proven targeting capabilities of monoclonal antibodies (mAbs), API is able to deliver its proprietary isotopes directly to tumor cells. This targeted therapy delivers a powerful focused energy to the selected cell, disrupting its internal machinery and thereby eliminating it from the patient’s body while sparing nearby healthy cells. |
It is widely recognized that alpha emitting isotopes have valuable qualities in medical treatment. We at Actinium Pharmaceuticals are proud of our history of working with the global leaders in this field to bring our therapies to greater numbers of patients and to apply our proven platform to more diseases. We invite you to learn more about our company, our technology, and our commitment to provide curative treatments for those afflicted with life threatening diseases with our powerful targeted therapeutics.